CSIMarket Company Name, Ticker, Suppliers, else..
 
Celcuity Inc   (NASDAQ: CELC)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $89.0600 $0.62 0.701%
Day's High: $89.80500030517578 Week Perf: -3.48 %
Day's Low: $ 87.01 30 Day Perf: 3.1 %
Volume (M): 785,768 52 Wk High: $ 151.02
Volume (M$): $ 0 52 Wk Avg: $96.59
Open: $87.61 52 Wk Low: $44.42



 Market Capitalization (Millions $) 4,850
 Shares Outstanding (Millions) 54
 Employees 155
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -193
 Cash Flow (TTM) (Millions $) 129
 Capital Exp. (TTM) (Millions $) 0

Business Description


Celcuity Inc is a biotechnology company that focuses on developing targeted therapeutics for the treatment of cancer. The company specializes in identifying and analyzing unique cellular signaling signatures found in patients' tumor cells. By understanding these signatures, Celcuity aims to develop personalized therapies that target specific molecular pathways and improve patient outcomes. The company utilizes its proprietary CELsignia platform to analyze tumor cells and identify potential therapeutic targets. Celcuity's ultimate goal is to revolutionize cancer treatment by advancing precision medicine and providing patients with more effective and personalized therapies.


   Company Address: 2800 Campus Drive Minneapolis 55441 MN
   Company Phone Number: 392-0123   Stock Exchange / Ticker: NASDAQ CELC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APRE   -0.62%    
CPRX        0.06% 
IOVA        1.36% 
ZYME        2.22% 
• View Complete Report
   



Clinical Study

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Ant...

Published Thu, Nov 27 2025 2:25 PM UTC

Advancements in Targeted Oncology: An Overview of Celcuity s Latest Findings and Future Directions Breast cancer remains one of the most prevalent and challenging malignancies to treat, requiring continuous efforts in research and development of new therapeutic strategies. Celcuity Inc., a clinical-stage biotechnology company, has positioned itself at the forefront of these...
Clinical Study

Detailed Results fromPIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate ...

Published Mon, Oct 20 2025 7:35 AM UTC

Pioneering Progress in Breast Cancer Treatment: Gedatolisib Shows Potential as a Game Changer: Recent findings from Celcuity Inc. regarding the efficacy of gedatolisib in treating hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), advanced breast cancer (ABC) have shown promising results. This article interprets the detailed results ...
Product Service News

Celcuity Prepares for Crucial NDA Submission of Gedatolisib Amid Financial Hurdles in Competitive Oncology S...

Published Thu, Aug 28 2025 10:53 AM UTC

In a significant development for cancer treatment, Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focusing on the development of targeted therapies for oncology, announced its plan to initiate a New Drug Application (NDA) submission for its investigational drug, gedatolisib. This submission is for the treatment of hormone receptor-positive, human epider...
Clinical Study

The exploration of novel therapeutic combinations for hormone receptor-positive (HR+), h...

Published Mon, Dec 30 2024 1:57 AM UTC

Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy for HR+, HER2- Advanced Breast Cancer: Insights from a Phase 1b Study The exploration of novel therapeutic combinations for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer remains crucial in improving patient outcomes, particularly i...
Clinical Study

Advancing the Frontiers of Breast Cancer Treatment: Celcuitys Phase 3 Clinical Trial f...

Published Thu, May 30 2024 11:00 AM UTC

Celcuity Inc., a pioneering clinical-stage biotechnology company specializing in the development of targeted therapies for oncology, has made a significant announcement that holds immense promise for patients with HR+/HER2- advanced breast cancer (ABC). The company has revealed plans to commence a Phase 3 clinical trial to investigate the efficacy of gedatolisib in combinati...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 90.62
PEG (TTM) -

Financial Strength Current
Quick Ratio 15.85
Working Capital Ratio 16.74
Leverage Ratio (MRQ) 6.5
Total Debt to Equity 6.04
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.02 $
Revenues (TTM) -
Cash Flow (TTM) 2.36 $
Cash 7.11 $
Book Value 0.98 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,244,426
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.